Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

51 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  February 28, 2019

The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Benzinga.com  February 28, 2019

10 Stocks Moving In Wednesday's After-Hours Session

Benzinga.com  February 27, 2019

Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia

Business Wire February 26, 2019

Gainey McKenna & Egleston Announces that It Filed a Class Action Lawsuit Against Celgene Corporation (CELG) And Its Directors

GlobeNewswire February 25, 2019

Merck To Buy Immune Design For $300M

Benzinga.com  February 21, 2019

Lifshitz & Miller LLP Announces Investigation of Celgene Corporation, SI Financial Group, Inc., Sparton Corporation, Western Gas Partners, LP, Wirecard AG, Yangtze River Port and Logistics Limited, and YRC Worldwide, Inc.

PR Newswire February 14, 2019

CELGENE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG

Business Wire February 11, 2019

January's Market Bounce Resulted In Some Unexpected Retail Trading Trends

Benzinga.com  February 5, 2019

Investor Movement Index January Summary

Benzinga.com  February 5, 2019

Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis

PR Newswire February 5, 2019

Pharma Catches Another Case Of M&A Fever

Benzinga.com  February 1, 2019

The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug

Benzinga.com  January 31, 2019

Celgene Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

Business Wire January 31, 2019

Earnings Scheduled For January 31, 2019

Benzinga.com  January 31, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Benzinga.com  January 27, 2019

Market Seems Generally Pleased With Earnings Results, But Geopolitics Still Weigh

Benzinga.com  January 24, 2019

Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug

Benzinga.com  January 24, 2019

INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Merger

PR Newswire January 13, 2019

CELGENE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG

PR Newswire January 8, 2019